Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics.
Status: Public
Caribou Biosciences
Caribou (NASDAQ: CRBU) is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies.
Cogent Biosciences
Cogent Biosciences (NASDAQ:COGT) (formerly Unum Therapeutics) is developing precision therapies for genetically defined diseases with a clinical stage therapy for systemic mastocytosis.
Adaptimmune
Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Adaptimmune was acquired by WorldMeds in 2025.
Flywire
Flywire (NASDAQ: FLYW) solves complex payment problems for businesses and institutions to empower new opportunities globally and locally. Its full-service billing, payment and receivables solutions connect all the entities involved to make those transactions faster, more secure, less expensive, and more transparent. Clients in a variety of industry verticals use Flywire’s platform to tailor the payment experience for their customers and to create a single point of visibility and control for payer engagement and receivables management – from invoicing and payment through reconciliation.
ViewRay
ViewRay (NASDAQ: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. Which uses a high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology.
Ultragenyx
Ultragenyx (NASDAQ: RARE) a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
Tetraphase Pharmaceuticals
Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
ReGenX Biosciences
ReGenX Biosciences (NASDAQ: RGNX) is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.